Home > Search Results: Stallings, R L.
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 3 records in 0.01 seconds.
Articles, 3 records found
Articles 3 records found  
1.
13 p, 6.2 MB Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma / Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Masanas, Marc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Boloix, Ariadna (Institut de Ciència de Materials de Barcelona) ; Masiá, Núria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; París-Coderch, Laia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Piskareva, Olga (Royal College of Surgeons in Ireland and National Children's Research Centre Our Lady's Children's Hospital. Molecular and Cellular Therapeutics) ; Jiménez Jiménez, Carlos (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Henrich, Kai-Oliver (German Cancer Research Center (DKFZ). Neuroblastoma Genomics Group) ; Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Westermann, Frank (German Cancer Research Center (DKFZ). Neuroblastoma Genomics Group) ; Stallings, Raymond L. (Royal College of Surgeons in Ireland and National Children's Research Centre Our Lady's Children's Hospital. Molecular and Cellular Therapeutics) ; Sábado, Constantino (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; de Toledo, Josep Sánchez (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Santamaría, Anna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Gallego, Soledad (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona ; Hospital Universitari Vall d'Hebron
The online version of this article (10. 1007/s00018-019-03041-4) contains supplementary material, which is available to authorized users.
Current therapies for most non-infectious diseases are directed at or affect functionality of the human translated genome, barely 2% of all genetic information. By contrast, the therapeutic potential of targeting the transcriptome, ~ 70% of the genome, remains largely unexplored. [...]
2019 - 10.1007/s00018-019-03041-4
Cellular and Molecular Life Sciences, Vol. 76 (february 2019) , p. 2231-2243  
Detailed record - Creative Commons
2.
17 p, 5.7 MB MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes / Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; París-Coderch, Laia (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Jubierre Zapater, Luz (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Martínez, Alba (Institut Català d'Oncologia) ; Zhou, Xiangyu (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Piskareva, Olga (Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland and National Children's Research Centre Our Lady's Children's Hospital) ; Bray, Isabella (Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland and National Children's Research Centre Our Lady's Children's Hospital) ; Vidal, Isaac (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Almazán-Moga, Anna (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Molist, Carla (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Roma, Josep (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Bayascas Ramírez, José Ramón. (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Casanovas, Oriol (Institut Català d'Oncologia) ; Stallings, Raymond L. (Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland and National Children's Research Centre Our Lady's Children's Hospital) ; de Toledo, Josep Sánchez (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Gallego, Soledad (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Segura, Miguel F. (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Vall d'Hebron Institut de Recerca (VHIR)
Despite multimodal therapies, a high percentage of high-risk neuroblastoma (NB) become refractory to current treatments, most of which interfere with cell cycle and DNA synthesis or function, activating the DNA damage response (DDR). [...]
2016 - 10.18632/oncotarget.7005
Oncotarget, Vol. 7 (january 2016) , p. 9271-9287  
Detailed record - Creative Commons
3.
12 p, 1.8 MB MYCN repression of Lifeguard/FAIM2 enhances neuroblastoma aggressiveness / Planells-Ferrer, L. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Urresti, J. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Reix, Stéphanie (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Murphy, D. M. (Royal College of Surgeons and National Children's Research Centre Our Lady's Children's Hospital) ; Ferreres Piñas, Joan Carles (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Borràs i Serres, Francesc Enric (Hospital Universitari Vall d'Hebron) ; Gallego, Soledad (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Stallings, R. L. (Royal College of Surgeons and National Children's Research Centre Our Lady's Children's Hospital) ; Moubarak, Rana S. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Segura, M. F. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Comella i Carnicé, Joan Xavier 1963- (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
Neuroblastoma (NBL) is the most common solid tumor in infants and accounts for 15% of all pediatric cancer deaths. Several risk factors predict NBL outcome: age at the time of diagnosis, stage, chromosome alterations and MYCN (V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma-Derived Homolog) amplification, which characterizes the subset of the most aggressive NBLs with an overall survival below 30%. [...]
2014 - 10.1038/cddis.2014.356
Cell death and disease, Vol. 5 (09 2014) , p. e1401  
Detailed record - Creative Commons

See also: similar author names
1 Stallings, R. L.
1 Stallings, R.L.
2 Stallings, Raymond L.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with